Myogenic progenitor cells derived from human induced pluripotent stem cell are immune-tolerated in humanized mice

Stem Cells Transl Med. 2021 Feb;10(2):267-277. doi: 10.1002/sctm.19-0452. Epub 2020 Sep 2.


It is still unclear if immune responses will compromise the large-scale utilization of human induced pluripotent stem cells (hiPSCs)-derived cell therapies. To answer this question, we used humanized mouse models generated by the adoptive transfer of peripheral blood mononuclear cells or the cotransplantation of hematopoietic stem cells and human thymic tissue. Using these mice, we evaluated the engraftment in skeletal muscle of myoblasts derived either directly from a muscle biopsy or differentiated from hiPSCs or fibroblasts. Our results showed that while allogeneic grafts were mostly rejected and highly infiltrated with human T cells, engraftment of autologous cells was tolerated. We also observed that hiPSC-derived myogenic progenitor cells (MPCs) are not targeted by autologous T cells and natural killer cells in vitro. These findings suggest that the reprogramming and differentiation procedures we used are not immunogenic and that hiPSC-derived MPCs will be tolerated in the presence of a competent human immune system.

Keywords: human induced pluripotent stem cells; humanized mice; myogenic progenitor cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adoptive Transfer
  • Animals
  • Cell Differentiation
  • Cellular Reprogramming
  • Fibroblasts
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Induced Pluripotent Stem Cells* / transplantation
  • Leukocytes, Mononuclear
  • Mice
  • Myoblasts
  • Thymus Gland / cytology

Grants and funding